Published in Br J Cancer on June 23, 2016
Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest (2017) 0.75
Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. Int J Mol Sci (2017) 0.75
Noncalcemic 20-hydroxyvitamin D3 inhibits human melanoma growth in in vitro and in vivo models. Oncotarget (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
TERT promoter mutations in familial and sporadic melanoma. Science (2013) 7.82
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Neoantigens in cancer immunotherapy. Science (2015) 5.16
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol (2014) 4.60
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015) 4.29
The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med (2015) 4.24
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science (2015) 4.23
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Adoptive cell transfer as personalized immunotherapy for human cancer. Science (2015) 3.19
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (2015) 3.12
Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet (2014) 2.86
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65
Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. Science (2015) 2.58
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell (2015) 2.12
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med (2015) 2.12
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. ACS Med Chem Lett (2012) 2.00
Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient. Proc Natl Acad Sci U S A (1984) 1.95
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95
Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat Commun (2012) 1.90
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell (2014) 1.88
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell (2015) 1.71
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity (2016) 1.69
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol (2013) 1.65
N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol (1989) 1.61
Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet (2014) 1.58
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol (2015) 1.54
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther (2009) 1.53
UV signature mutations. Photochem Photobiol (2014) 1.52
Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest (2015) 1.41
Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev (2012) 1.40
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov (2015) 1.30
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene (1989) 1.30
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene (2013) 1.25
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet (2015) 1.24
Biomarkers in cancer immunotherapy. Cancer Cell (2015) 1.16
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet (2015) 1.15
RAF inhibitors that evade paradoxical MAPK pathway activation. Nature (2015) 1.12
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. Clin Cancer Res (2015) 1.05
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer (2015) 1.03
No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol (2014) 0.98
Systematic Screening of Promoter Regions Pinpoints Functional Cis-Regulatory Mutations in a Cutaneous Melanoma Genome. Mol Cancer Res (2015) 0.95
BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell Melanoma Res (2014) 0.94
Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A (2015) 0.93
A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget (2014) 0.92
Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin. J Cutan Pathol (1997) 0.90
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget (2015) 0.85
What's new in melanoma? Combination! J Transl Med (2015) 0.85
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Crit Rev Oncol Hematol (2015) 0.83
Recurrent inactivating RASA2 mutations in melanoma. Nat Genet (2015) 0.83
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Mol Cancer Ther (2015) 0.82
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clin Cancer Res (2016) 0.82
Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J (2016) 0.80
Frequent DPH3 promoter mutations in skin cancers. Oncotarget (2015) 0.78
Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. Lancet Oncol (2015) 0.77
Biomolecules. The dark side of sunlight and melanoma. Science (2015) 0.75